Introduction
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a transcription factor that mediates an adaptive response induced by heterodimerization at antioxidant response elements (AREs) located in proximal promoters of the target genes that detoxify oxidants and electrophiles (Venugopal and Jaiswal, 1998) . The observation that Nrf2 null mice are viable and fertile (Chan et al., 1996) indicates that inducible ARE-dependent gene transcription is dispensable under homeostatic conditions. However, failure to induce Nrf2 and its target genes increases the susceptibility of Nrf2 null mice to electrophilic carcinogens (Ramos-Gomez et al., 2001) . Induction of ARE-mediated gene expression represents the current paradigm describing Nrf2's primary physiological role.
Nrf2 expression is deregulated in human cancer. Nrf2 is elevated in some breast and lung cancers (Padmanabhan et al., 2006; Singh et al., 2006; Nioi and Nguyen, 2007) . In non-small-cell lung cancer, Nrf2 overexpression can be a consequence of mutations in Keap1 that impede Nrf2 ubiquitination (Padmanabhan et al., 2006; Singh et al., 2006; Nioi and Nguyen, 2007) or a consequence of Nrf2 mutations that impair Nrf2's ability to bind to Keap1 . Nrf2 overexpression in non-small-cell lung cancer is postulated to promote tumor growth because repression of Nrf2 expression in non-small-cell lung cancer xenografts has been shown to inhibit tumor proliferation (Singh et al., 2008) .
As expected, given the complexity of tumorigenesis, there are tumors in which Nrf2 expression is suppressed. Stacy et al. (Stacy et al. 2006) found that approximately 7% of the human head and neck squamous cell carcinomas expressed low levels of Nrf2, coincident with Keap1 overexpression (Stacy et al., 2006 ). An Oncomine bioinformatics analysis (http://ww.oncomine.org) revealed that Nrf2 was downregulated in lung adenocarcinoma (Beer et al., 2002) , ovarian serous adenocarcinoma, ovarian endometrioid adenocarcinoma and clear cell adenocarcinoma (Welsh et al., 2001; Hendrix et al., 2006) , as well as hepatocellular carcinoma (Chen et al., 2002; Wurmbach et al., 2007) . Nrf2 and its target genes have been shown to be downregulated in human prostate tumors, in metastatic prostate cancer (Frohlich et al., 2008) and in the TRAMP mouse prostate tumor model (Frohlich et al., 2008; Yu et al., 2010) . Nrf2 suppression can be a consequence of CUL3 overexpression (Loignon et al., 2009) or epigenetic events (Yu et al., 2010) . The biochemical pathways impacted by Nrf2 deregulation during tumorigenesis are not well understood.
In this report we show that gene-mediated repression of Nrf2 in subpopulations of oncogenic cells grown in culture can increase their propensity for survival and motility. RNA-interference (RNAi)-mediated suppression of Nrf2 in an oncogenic Ras context was associated with increased levels of reactive oxygen species (ROS), increased survival and colony outgrowth. Cells expressing Nrf2 short hairpin RNA (shRNA) exhibit high levels of Smad phosphorylation in both the linker region and the C-terminus, elevated synthetic (CAGA) luciferase reporter activity and elevated expression of endogenous plasminogen activator inhibitor (PAI)-1. We found that Nrf2/Smad3/Smad4 formed an immunoprecipitable nuclear complex and that wild-type but not dominant-negative Nrf2 (Yu et al., 2000) , suppressed CAGA-directed reporter activity. RNAi-mediated suppression of Nrf2 was associated with increased expression of Slug and subsequent repression of E-cadherin. Functional studies revealed that loss of Nrf2 was accompanied by a high propensity for Smad-mediated motility. These results support the hypothesis that suppression of Nrf2 contributes to tumor cell plasticity and motility, in part through exuberant Smad-mediated signaling.
Results

Cellular plasticity and motility
The Cullin3 adaptor protein, Keap1, directs E3-ubiquitin ligase-mediated ubiquitylation and proteasomedependent degradation of Nrf2 (Kobayashi et al., 2004) . Keap1 overexpression has been shown to repress expression of Nrf2 and its target genes (Zhang et al., 2004) . Keap1 overexpression has been observed in human cancer (Stacy et al., 2006) , including metastatic hepatocellular carcinomas (http://www.oncomine.org) (Ye et al., 2003) . FLAG-tagged Keap1 or FLAG-tagged luciferase was stably expressed in HepG2 cells, as described in Sekhar et al. (2003) . As determined by quantitative image analysis, stable expression of FLAG/Keap1 reduced Nrf2 levels by 60% relative to the expression of b-actin and compared with control cells stably expressing FLAG/luciferase (Figure 1a ). Loss of Nrf2 produced a statistically significant decrease in the activity of an Nrf2-regulated ARE-directed reporter (Sekhar et al., 2003) . GCLC, the catalytic subunit for glutamate cysteine ligase, the rate limiting enzyme in glutathione synthesis, is an Nrf2 target gene. Keap1-mediated repression of Nrf2 suppressed endogenous GCLC expression (Sekhar et al., 2003) . Multidrug resistance-associated proteins are also Nrf2 target genes (Hayashi et al., 2003) . Loss of Nrf2 decreased cellular multidrug resistance-associated proteins activity (Sekhar et al., 2003) . These data indicate that overexpression of Keap1 repressed the expression of Nrf2 and several surrogate Nrf2 target genes.
Cells that overexpressed Keap1 exhibited increased survival when plated as single cells (Figure 1 ). The cells changed to a spindle-like morphology with extended cellular pseudopodium characteristic of migrating cells (Greenburg and Hay, 1982) , as assessed by phase microscopy (Figure 1d ) or immunofluorescence (Supplementary Figure 1A ). Changes in morphology were not observed in HepG2 cells stably expressing FLAG/ luciferase, non-transformed HEK293 cells stably expressing FLAG/Keap1 (Hong et al., 2005) or nontransformed NMuMG cells that stably expressed FLAG/Keap1 (data not shown).
Overexpression of Keap1 in human colon colonic carcinooma cell lines (caco-2) carcinoma cells repressed Nrf2 and its target genes, resulting in cellular remodeling (Kusano et al., 2008) . This change in cell morphology was (Kusano et al., 2008) . As HepG2 cells express low E-Cadherin levels due to loss of connexin 26 (Yano et al., 2001) , we evaluated another marker of cellular remodeling, vimentin, the expression of which increases following the loss of cell-cell adhesion (Zavadil and Bottinger, 2005) . Overexpression of Keap1 was associated with upregulation of vimentin (Supplementary Figure 1B) . Keap1 also directs the ubiquitylation of PGAM5 (Lo and Hannink, 2006) , Fetal Alz-50 reactive clone 1 (Strachan et al., 2005) , IKK b (Lee et al., 2009 ) and p62 (Komatsu et al., 2010) . The changes in cellular morphology could be a direct consequence of the loss of Nrf2 or a secondary consequence of increased degradation of the other substrates. Therefore, human A549 non-small cell lung carcinoma cells were made use of, in which Keap1 contains a G to C mutation at residue 333 that impairs its ability to direct substrate ubiquitylation (Singh et al., 2006) .
Several different non-overlapping shRNA/siRNA sequences were used to stably knock-down Nrf2 in A549 cells. Cells were transduced or transfected with retrovirus vector expressing Nrf2 shRNA, transfected with pSilencer vector expressing Nrf2 siRNA (Singh et al., 2008) , or a pool consisting of four lentiviruses each expressing a different Nrf2 shRNA. Control cells were transduced or transfected with the appropriate control vectors. Drug selection of Nrf2 shRNA or siRNA expressing cells yielded large dense foci, which were isolated and expanded. In cells transduced with control non-silencing vector, only small discrete colonies were observed. Therefore, a polyclonal population stably expressing control non-silencing shRNA was obtained.
Stable expression of Nrf2 shRNA or siRNA repressed Nrf2 expression and suppressed the Nrf2 target gene GCLC (Figure 2a ). Loss of GCLC was followed by a 70% decrease in the intracellular glutathione (Po0.05; Student's t test; Supplementary Figure 2A ). As expected, suppression of GCLC and other Nrf2 target genes increased intracellular ROS, as determined by the 10-fold increase in C-400 fluorescence (Po0.05 Student's t-test; Supplementary Figures 2B and C) . Oxidative stress is known to activate AKT (Wang et al., 2000) . Activated AKT accelerates mitochondrial ROS generation, resulting in a cycle of oxidant-induced PTEN inactivation and sustained AKT activation (Nogueira et al., 2008) . Consistent with increased ROS observed in Supplementary Figure 2 , immunoblotting revealed elevation of phospho-AKT, Cyclin D1 (Matsuzawa and Ichijo, 2008 ) and c-Jun in Nrf2 shRNA expressing cells compared with control ( Supplementary  Figure 3 ). Figure 4B ) did not significantly affect the rate of cell proliferation on a plastic substrate, compared with control, non-silencing shRNA (population doubling time of 19 h). Thus, the increased proliferation observed in cells that overexpress Keap1 cannot be attributed to the loss of Nrf2.
Cells stably expressing independent Nrf2 shRNA from retrovirus or Nrf2 siRNA from a pSilencer vector (Singh et al., 2008) exhibited an anchorage-independent phenotype such that when plated as single cells in soft agar, they formed large colonies (Po0.0001, Student's t-test; Figure 2b ).
ShRNA-containing cells exhibited a spindle-like morphology with extended cellular pseudopodium characteristic of migrating cells (Figure 2c ). The change in morphology was not a consequence of transduction. A549 cells were transfected rather than transduced with the retrovirus shRNA vectors. Cells stably transfected with Nrf2 shRNA exhibited a morphology similar to cells that were transduced with Nrf2 shRNA (data not shown).
SW480 colon carcinoma cells are deficient in transforming growth factor-b1 type II receptor function, functional Smad4 and E-cadherin expression (Calonge and Massague, 1999; Muller et al., 2002) . These cells exhibit a spindle-like morphology (Muller et al., 2002; Shiou et al., 2007) . The forced expression of Smad4 in these cells restores the expression of E-cadherin in a TGF-b1 type II receptor-independent manner (Calonge and Massague, 1999; Muller et al., 2002) and the cells acquire an epithelioid morphology (Shiou et al., 2007) . SW480 cells stably expressing Smad4 (Shiou et al., 2007) were transduced with either Nrf2 shRNA or control non-silencing vectors. Expression of Nrf2 shRNA reduced Nrf2 expression by 50%, as quantitated by immunoblotting. Loss of Nrf2 in SW480 cells expressing Smad4 was accompanied by a change in morphology: from epithelioid-like to spindle-like (Supplementary Figure 5) .
A transwell migration assay was used to assess migration of A549 and HepG2 cells (Figures 3a and  b ). Migration through transwell inserts was assessed 24 h after inoculation. A549 cells stably expressing Nrf2 shRNA exhibited a four-fold increase in migration compared with control. HepG2 cells expressing FLAG/ Keap1 exhibited an 18-fold increase in migration compared with control HepG2 cells expressing FLAG/ luciferase (Figure 3 , Po0.05; Student's t test). A twodimensional migration assay was used to assess migration. Loss of Nrf2 increased cellular motility (Figures 3c  and d ). An area devoid of cells was created at time 0 by scraping a monolayer of cells. The leading edges along the scraped area had almost coalesced 24 h after scraping the cells expressing Nrf2 shRNA from lentivirus ( Figure 3c ), retrovirus (Supplementary Figure 6A ) or Nrf2 siRNA from pSilencer (Supplementary Figure  6B ), or overexpressing Keap1 (Figure 3d ). Cells expressing control non-silencing shRNA/siRNA exhibited little migration. The observation that exposure of the control cells to TGF-b (5 ng/ml) induced migration whereas addition of TGF-b plus the TGF-b receptor kinase inhibitor SB-431542 (10 mM) inhibited migration, indicates that cells expressing non-silencing shRNA retain the ability to migrate (Supplementary Figure 6C ).
SIS3 is a small-molecule inhibitor of receptormediated phosphorylation of the Smad3 SSXS motif (Jinnin et al., 2006) . SIS3 inhibits TGF-b receptormediated association of phospho-Smad3 with Smad4 and Smad-dependent transcriptional activation (Jinnin , 2006) . SIS3 was found to inhibit phosphorylation of Smad2 and Smad3 in A549 cells (data not shown) and in Nrf2 shRNA-expressing cells (Figure 4a ). Use of SIS3 attenuated migration of cells stably expressing Nrf2 shRNA (Clone #2), as assessed using the two-dimensional migration assay (Figures 4b-f ). As a control for this experiment, cells stably expressing control shRNA were exposed to 5 ng/ml TGF-b1 for 24 h in the absence or presence of SIS3. Exposure to TGF-b1 enhanced cell migration, whereas SIS3 exposure attenuated TGF-b1mediated migration ( Supplementary Figure 7) .
We developed a novel methodology to interrogate cellular motility and plasticity. A microfabricated device, termed the m-Taur, was designed to assay a cell's ability to migrate through narrow three-dimensional channels of various dimensions. The device (see the schematic in Supplementary Figure 8 and Supplementary Information) consists of a central channel into which cells are loaded. Three pairs of chambers, located on either side of the central loading channel, contain arrays of posts that are manufactured to various dimensions. Figure 5a illustrates a central channel and two opposing chambers, and the inset shown in Figure 5b shows a higher magnification of the rows of posts and a single cell. The opposing chambers in Figure 5a have a series of posts with dimensions of 12 Â 12 Â 13 mm 3 (width Â length Â height). The interpost gaps have the same dimensions as the posts. Each m-Taur has two additional opposing chambers having interpost dimensions of 10 Â 10 Â 13 mm 3 ; and 8 Â 8 Â 13 mm 3 (not shown). Thus, cells have to change from a cortical shape to an elongated shape in order to squeeze between the two posts. Migration through the chambers was determined 16 h after loading. As shown in Figures 5a and b, A549 cells expressing control non-silencing shRNA could not progress through the first line of posts with interpost dimensions of either 12 Â 12 Â 13 mm 3 or 8 Â 8 Â 13 mm 3 . In contrast, cells expressing Nrf2 shRNA had migrated through seven sets of 12 Â 12 Â 13 mm 3 posts 16 h after loading (Figure 5c ). Cell migration was slower when the interpost distances were 8 Â 8 Â 13 mm 3 ; the cells had migrated through only three sets of posts (Figure 5d ). Please note that control cells loaded into the central loading channel were distributed throughout the loading channel and that some chambers had more cells in front of them than others. This is illustrated in the control samples by inspection of Figures 5a and b . These results lead to the hypothesis that repression of Nrf2 increases cellular plasticity.
We utilized a TGFb1 enzyme-linked immunosorbent assay (Biswas et al., 2007) to determine whether the changes in motility were autocrine in origin. Cells stably expressing Nrf2 shRNA secreted slightly less TGF-b1 compared with control (Po0.05 Student's t-test; Supplementary Figure 9 ). Therefore, TGF-b1 autocrine effects could be ruled out.
Cell-cell adhesion
A migratory phenotype is often associated with loss of cell-cell adhesion (Yang and Weinberg, 2008) . A549 Figure 4 Inhibition of Smad3 activity attenuates the migration of A549 cells stably expressing Nrf2 shRNA. (a) Nrf2 expressing shRNA cells were exposed to 10 mM SIS3 for the indicated number of times. Cells were immunoprecipitated with antibody to pSmad2/3 and then immunoblotted with antibody to pSmad2/3. (b-f) Cells were subjected to the scrape assay. The assay was performed in the absence (b, c, e) or presence of 10 mM SIS3 (d, f). Migration was assessed 24 or 48 h after scraping. cells expressing Nrf2 shRNA exhibited a loss of E-cadherin expression, as determined by both immunofluorescence and immunoblotting (Figures 6a and b) .
The zinc finger protein, Slug, is one of several proteins that repress E-cadherin expression (Peinado et al., 2007) . Immunoblotting revealed that loss of Nrf2 was (Figure 6c ). We found that transfection of a vector expressing human Nrf2 along with a luciferase reporter under the control of the human E-cadherin promoter induced reporter activity (Po0.05; Student's t test; Figure 6d ). The E-cadherin gene has not been reported to be regulated by an ARE in its promoter. Use of promoter analysis software did not reveal the presence of an ARE consensus sequence (data not shown). Thus, the data support the hypothesis that loss of Nrf2 impacts E-Cadherin expression indirectly. Thuault et al.(2006) have shown that Slug expression is positively regulated by HMGA2, which itself is induced by Smad2/3/4-dependent signaling. Smad-dependent signaling occurs in response to receptor-mediated phosphorylation of Smad2 and Smad3 at two serine residues at the C-terminus, with subsequent heterodimerization or heterotrimerization with Smad4 (Thuault et al., 2006) . As shown in Figure 7a , nuclei isolated from cells expressing Nrf2 shRNA exhibit high levels of C-terminus Ser465/467 phospho-Smad2 and Ser423/425 phospho-Smad3 compared with control. Matsuzaki et al.(2009) have shown that simultaneous linker region and C-terminus phosphorylation correlate with increased malignant Smad signaling. Phosphoryla-tion of Ser245/250/255 in the linker region of Smad2 was also increased in Nrf2 shRNA containing cells. We interpret the presence of two immunoreactive bands in the pSer245/250/255 immunoblot to be a consequence of phosphorylation at both the linker region and C-terminus.
Smad phosphorylation and transcriptional responses
We found that transfection of a synthetic (CAGA) luciferase reporter (Mithani et al., 2004) into Nrf2 shRNA-expressing cells yielded an activity that was fivefold greater than that observed in control cells (Figure 7b, Po0.001, Student's t test) . The CAGA-LUC reporter activity reflects the presence of endogenous TGF-b present in the serum of the growth medium, as well as enhanced R-Smad phosphorylation. The type 1 PAI-1 promoter contains a cis element responsive to a complex that includes phospho-Smad3 and -Smad4 (Song et al., 1998) . Therefore, we interrogated the expression of endogenous PAI-1 in Nrf2 shRNAexpressing cells. The immunoblot shown in Figure 7c indicates that PAI-1 expression is increased in Nrf2repressed A549 cells.
Nrf2 belongs to the basic leucine zipper family of transcription factors (Moi et al., 1994) and has been shown to form heterodimers with c-Jun, JunB and JunD, as well as ATF3 (Venugopal and Jaiswal, 1998; Brown et al., 2008) . It has been shown that Smad3 binds to ATF3 (Kang et al., 2003) as well as the Jun family Nrf2 and Smad signaling G Rachakonda et al (Liberati et al., 1999) . The MH1 domain of Smad3 binds directly to the leucine zipper domain of the bZip proteins ATF2 and c-Jun (Grinberg and Kerppola, 2003) . Therefore, one may hypothesize that Smad3 may reside in a complex with the bZip leucine zipper protein Nrf2. Immunoprecipitation of endogenous Smad3 from A549 nuclear lysates followed by immunoblotting demonstrated the presence of Smad4 and Nrf2 in the immunoprecipitate (Figure 8a) . FLAG/Smad3 and Nrf2 were either co-transfected or transfected alone into NMuMG cells. Co-transfection followed by immunoprecipitation of FLAG/Smad3 and immunoblotting for Nrf2 confirmed the association of Smad3 with Nrf2 (Figure 8b ). We also interrogated H460 cells. Similar results were obtained with H460 nuclear lysates.
A549 cells were treated with 2 ng/ml of TGF-b, washed and solubilized in cell lysis buffer (see Supplementary Methods). GST or GST/Nrf2, immobilized on GSH-agarose beads (Brown et al., 2008) , was used to capture soluble protein. The captured protein was immunoblotted using an antibody to C-terminus phospho-Smad2/3 (Figure 8c ). We observed immunoreactive proteins of approximately 55 and 60 kDa (arrows Figure 8c ). We interpret these phosphoproteins to be pSmad3 and pSmad2 respectively. We also observed an immunoreactive phosphoprotein that migrated just above pSmad2, which we interpret to be Smad2 phosphorylated in both the linker region and the C-terminus.
The observation that Smad3, Smad4, and Nrf2 resided in a complex prompted us to determine whether Nrf2 impacted Smad-mediated transcription. A549 cells were co-transfected with vectors expressing a synthetic (CAGA) luciferase reporter, Renilla luciferase reporter, Smad3, and wild-type or dominant negative Nrf2 (Yu et al., 2000) (Figure 8d ). CAGA-LUC reporter activity (Mithani et al., 2004) was inhibited 70% when wildtype but not dominant-negative Nrf2 was ectopically overexpressed (P ¼ 0.001, Student's t-test). Transfection of Smad3 increased CAGA-LUC reporter activity by 2.6fold (P ¼ 0.002, Student's t test). However, co-transfection of wild-type Nrf2 but not dominant-negative Nrf2 (amino acids 399-589 (Yu et al., 2000) ) inhibited Smad3mediated transcription (P ¼ 0.004, Student's t-test). These data show that Nrf2 negatively impacts transcription mediated by R-Smad/Smad4. Figure 8 Nrf2 is found in a complex with Smad3 and Smad4 and suppresses the activity of a luciferase reporter under the control of a synthetic CAGA promoter. (a) Immunoprecipitation of endogenous Smad3 from A549 cell lysates followed by immunoblotting for Smad4 and Nrf2. (b) FLAG/Smad3 and Nrf2 were either co-transfected or transfected alone into NMuMG cells. FLAG/Smad3 was then immunoprecipitated and immunoblotted for Nrf2. Endogenous Smad3 was immunoprecipitated from H460 cells and then immunoblotted for Nrf2. (c) A549 cells were treated with 2 ng/ml TGF b and solubilized. Cell protein was subjected to GST or GST/ Nrf2 pulldown and immunoblotted to pSmad2/3 antibody. (d) Wild-type A549 cells were transiently co-transfected with a luciferase reporter under the control of a synthetic CAGA reporter, a vector expressing b-galactosidase, vectors expressing Smad3, wild-type human Nrf2, dominant-negative Nrf2, or insertless pcDNA3.1. Reporter activity was determined 72 h after transfection.
Discussion
The consequences of Nrf2 deregulation in tumor etiology are just beginning to be explored. Exuberant Nrf2/ARE-directed gene expression in human head and neck cancer is associated with recurrence-free survival (Chung et al., 2004) . Conversely, loss of Nrf2/AREdirected gene expression, with subsequent elevation of reactive oxygen species has been shown to represent a primary oncogenic-associated stress that promotes proliferation and motility (Sun et al., 1989; Szatrowski and Nathan, 1991; Zhang et al., 2002; Liu et al., 2004; Radisky et al., 2005; Weydert et al., 2006; Cao et al., 2009; Luo et al., 2009) . For example, loss of MnSOD results in increased ROS levels, which in turn stimulate cyclins D1 and B1, making cells insensitive to antigrowth signals (Sarsour et al., 2008) . Conversely, expression of MnSOD with subsequent suppression of ROS allows cells to respond to anti-proliferation signaling. Mates et al. (2008) argue that the majority of ROS effects are a consequence of signaling pathway alterations rather than non-specific damage of macromolecules. ROS can function in an autocrine manner by reversibly altering the function of phosphatases and kinases (Kamata et al., 2005; Tonks, 2005; Mates et al., 2008) .
The exuberant levels of ROS found in many tumor cells (Szatrowski and Nathan, 1991) can be a consequence of diminished expression of Nrf2-regulated genes involved in ROS detoxification Hirayama et al., 2003) . Restoration of ROS to physiological levels by overexpression of Nrf2-regulated-antioxidant proteins can lower ROS levels coincident with suppression of oncogenesis in such cancers as pancreatic, glioma and melanoma (Chakraborty et al., 1992; Zhang et al., 2002; Liu et al., 2004) .
Consistent with these observations, Coulouarn et al. (2008) found that loss of Nrf2 expression is associated with increased progression of human hepatocellular carcinomas, and is a component of a multi-gene signature that is predictive of TGF-b1-mediated invasiveness and metastasis. Loss of Nrf2 and Nrf2 target gene expression in the transgenic adenocarcinoma of the the mouse prostate mouse model has led Barve et al. (2009) to hypothesize that loss of Nrf2 contributes to high grade PIN and tumor formation.
The results presented in this investigation indicate that suppression of Nrf2 via overexpression of Keap1 in HepG2 cells or RNAi-mediated suppression of Nrf2 in A549 or SW480 cells was accompanied by acquisition of anchorage-independent cell growth, morphological plasticity and enhanced Smad-mediated motility.
Interestingly, transient siRNA-mediated repression of Nrf2 in human lung cancer cell lines, including A549 cells, diminished proliferation and resistance to certain chemotherapeutic drugs Shibata et al., 2008; Homma et al., 2009) . We hypothesize that the differences in proliferation observed by these investigators and the work reported here may be attributed to transient vs stable repression of Nrf2. Singh et al. (2008) stably expressed an Nrf2 siRNA vector in A549 and H460 cells. Knock down of Nrf2 in these cells was accompanied by a loss of proliferation and an inability to grow in soft agar. In addition, when these cells were grown as xenografts, tumor formation was inhibited (Singh et al., 2008) . The differences in soft agar growth observed by Singh et al. (2008) and in the work presented here are not currently understood. Our study utilized cell culture models only and did not investigate xenograft growth.
TGF-b signaling represents one important regulator of cell motility, and as discussed in Safina et al. (2009) involves R-Smads, Smad4 and PI3 kinase, as well as p38. As Valcourt et al. have shown that TGF-b/R-Smads/Co-Smad signaling is intimately involved in cellular processes that enhance tumor cell motility, we focused on this pathway. Immunoprecipitation assays were used to show that Nrf2 resides in a complex with phospho-R-Smads and Co-Smad4. Although the mechanism responsible for enhanced R-Smad phosphorylation has not been investigated in this study, one may postulate that the R-Smad dephosphorylation by cellular phosphatases may be inhibited as a consequence of elevated cellular ROS. As simultaneous linker region/ C-terminus phosphorylation is not observed in nontransformed cells, we postulate that differential linker region/C-terminus phosphorylation may be the mechanism that distinguishes the differential results obtained in tumorigenic vs non-transformed cells.
Ectopic expression of wild-type but not dominantnegative Nrf2 dampened the activity of a synthetic CAGA-directed luciferase reporter. Conversely, shRNA knockdown of Nrf2 in tumor cells enhanced the activity of the synthetic CAGA-directed reporter, Dominantnegative Nrf2, which contains the CNC homology region and the DNA-binding leucine zipper motif but is missing the Neh4 and Neh5 transactivation domains, was not able to function antagonistically. The Neh4 and Neh5 domains of Nrf2 recruit p300/CBP (Katoh et al., 2001) . In the nucleus the Smad3/Smad4 oligomers also recruit the coactivators p300/CBP. This interaction results in the acetylation of Lys 378 of Smad3 and promotion of transcriptional activity (Inoue et al., 2007) . A competition between DNA-bound Smad3 complexes and Nrf2/Smad complexes for CBP/p300 is one possibility that may contribute to the results presented herein. Another possibility relates to the work of Verrecchia et al. (2001) : Smad3/Nrf2 may form immunoprecipitable 'off-DNA' complexes that downregulate gene transcription driven by Smad binding sequences.
Suppression of Nrf2 was found to enhance the expression of the endogenous Smad target genes PAI-1 and Slug, while suppressing endogenous E-cadherin and an E-cadherin luciferase reporter. Consistent with these observations, transient ectopic expression of Nrf2 enhanced the activity of an E-cadherin reporter. Functional assays revealed that RNAi-mediated knockdown of Nrf2 in cell culture was accompanied by increased Smad-mediated tumor cell motility.
In summary, the data presented herein support a new and novel dimension to the Nrf2 paradigm: in the context of oncogenesis these data lead to the hypothesis that suppression of Nrf2 expression in tumor cells can increase cell plasticity and motility, because of malignant Smad signaling. Supplementary Figure 10 illustrates the signaling pathways impacted by the loss of Nrf2 in this investigation.
Materials and methods
Cells, plasmids, and antibodies HepG2 cells, characterized by dominant-acting N-Ras (Huber and Thorgeirsson, 1987) , were maintained in DMEM. A549 cells, characterized by an activating K-Ras mutation (Valenzuela and Groffen, 1986) , were maintained in RPMI 1640 medium. SW480 cells express activating K-Ras were maintained as described (Shiou et al., 2007) . The cDNA KIAA0132 (human Keap1) was a gift from Dr Takahiro Nagase and was subcloned into pCMV-Tag (Stratagene, Santa Clara, CA, USA). The vector pCMV-Tag places a FLAG epitope NH2 terminus to Keap1. pCMV-Tag/luciferase was obtained from Stratagene. pcDNA/V5mNrf2 was a gracious gift from Dr M McMahon. The CAGA-LUC reporter was used as described in Mithani et al. (2004) . GST and GST/Nrf2 are described in Brown et al. (2008) . The NFE2L2 (Nrf2) pSM2 retroviral shRNAmir clone V2HS_64255 (sense sequence 5 0 -CCATT GATGTTTCTGATCT -3 0 ) and the target set Nrf2 pGIPZ lentiviral shRNAmir (Sense sequences 5 0 -GCTGCTCA GAATTGCAGAA-3 0 ; 5 0 -CTGAGTTACAGTGTCTTAA-3 0 ; 5 0 -CTCCTACTGTGATGTGAAA-3 0 ; 5 0 -CAGTTGACAGTGA ACTCAT -3 0 ), and corresponding non-silencing controls were obtained from Open Biosystems. pSilencer (Applied Biosystems, Foster City, CA, USA) was used to express Nrf2 siRNA (sense sequence 5 0 -GATCCGTAAGAAGCCAGATGTTAATTCAA GAGACATTCTTCGGTCTACAATTTTTTTTGGAAA-3 0 ) or appropriate controls as described in Singh et al. (2008) .
Antibodies were obtained as follows: Nrf2 (Santa Cruz, Biotechnology, Santa Cruz, CA, USA: Cat# sc-13032; Abcam: Cat #ab62352), GCLC (Neomarkers, Fremont, CA, USA: Cat # P1697) and b-actin (Sigma: St Louis, MO, USA, Cat #A5441). The following antibodies were obtained from Cell Signaling, Danvers, MA, USA: pAKT (Cat #9275S), AKT (Cat #9272), E-cadherin (Cat #610404), pSmad2 (ser245 Cat #3104S, Ser 465 Cat #3101S), Smad2 (Cat #3103), pSmad3 (Ser 423 Cat #9520S), Smad3 (Cat #9523S), Smad 4 (Cat #9515), cyclin D (Cat #2926), and Lamin A/C (Cat #2032). The following antibodies were obtained from Santa Cruz: PAI-1 (#sc8979), SLUG (#sc-15391), c Jun ((#822), Keap1 (#sc15246), pSmad2/3 (Ser423/425) (#sc-11769) and GAPDH (#sc32233).
mTaur device
The device is made using standard photolithographic techniques with a two-layer deposition of SU8-2010 photo-resist (Whitesides et al., 2001) . Cells were loaded into the device and the device was placed in an incubator for approximately 3 h. The device was then placed in an Axiovert 200M microscope (Carl Zeiss Microlmaging, Thornwood, NY, USA), which was maintained a temperature of 37 1C. For detailed information please refer Supplementary Information.
Details regarding the methods used for other experiments are provided in Supplementary Information.
